Logo

ABBV

AbbVie Inc.

ABBV

AbbVie Inc. • NYSE
$227.70 ▲ 0.02% (+0.04)
Market Cap $402.40 B
52w High $244.81
52w Low $164.39
Dividend Yield 6.92%
P/E 172.5
Volume 2.61M
Outstanding Shares 1.77B

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $15.776B ▲ $7.495B ▲ $186M ▼ 1.179% ▼ $0.1 ▼ $3.444B ▼
Q2-2025 $15.423B ▲ $7.158B ▲ $944M ▼ 6.121% ▼ $0.53 ▼ $4.344B ▼
Q1-2025 $13.343B ▼ $5.608B ▼ $1.286B ▲ 9.638% ▲ $0.72 ▲ $4.4B ▲
Q4-2024 $15.102B ▲ $12.196B ▲ $-22M ▼ -0.146% ▼ $-0.018 ▼ $535M ▼
Q3-2024 $14.46B $6.417B $1.561B 10.795% $0.88 $4.883B

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $5.671B ▼ $133.898B ▼ $136.497B ▼ $-2.642B ▼
Q2-2025 $6.467B ▲ $137.182B ▲ $137.32B ▲ $-183M ▼
Q1-2025 $5.176B ▼ $136.165B ▲ $134.703B ▲ $1.42B ▼
Q4-2024 $5.555B ▼ $135.161B ▼ $131.797B ▼ $3.325B ▼
Q3-2024 $7.285B $143.422B $137.351B $6.032B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $188M ▼ $7.024B ▲ $-3.264B ▼ $-4.59B ▼ $-838M ▼ $7.528B ▲
Q2-2025 $941M ▼ $5.153B ▲ $-1.181B ▼ $-2.71B ▼ $1.292B ▲ $4.884B ▲
Q1-2025 $1.289B ▼ $1.635B ▼ $-735M ▲ $-1.258B ▲ $-349M ▲ $1.4B ▼
Q4-2024 $4.286B ▲ $7.048B ▲ $-1.874B ▲ $-6.861B ▼ $-1.733B ▲ $6.757B ▲
Q3-2024 $1.59B $5.447B $-8.256B $-3.072B $-5.873B $5.198B

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
AlphaganCombigan
AlphaganCombigan
 $80.00M ▲$60.00M ▼$40.00M ▼$50.00M ▲
Botox Cosmetic
Botox Cosmetic
 $690.00M ▲$560.00M ▼$690.00M ▲$640.00M ▼
Botox Therapeutic
Botox Therapeutic
 $870.00M ▲$870.00M ▲$930.00M ▲$980.00M ▲
Duodopa
Duodopa
 $110.00M ▲$100.00M ▼$100.00M ▲$100.00M ▲
H U M I R A
H U M I R A
 $1.68Bn ▲$1.12Bn ▼$1.18Bn ▲$990.00M ▼
Imbruvica
Imbruvica
 $850.00M ▲$740.00M ▼$750.00M ▲$710.00M ▼
Juvederm Collection
Juvederm Collection
 $280.00M ▲$230.00M ▼$260.00M ▲$250.00M ▼
LinzessConstella
LinzessConstella
 $230.00M ▲$150.00M ▼$260.00M ▲$330.00M ▲
LumiganGanfort
LumiganGanfort
 $120.00M ▲$110.00M ▼$100.00M ▼$100.00M ▲
MAVYRET
MAVYRET
 $290.00M ▲$310.00M ▲$380.00M ▲$310.00M ▼
Other Aesthetics
Other Aesthetics
 $330.00M ▲$320.00M ▼$330.00M ▲$300.00M ▼
Other Eye Care
Other Eye Care
 $210.00M ▲$220.00M ▲$250.00M ▲$250.00M ▲
Other Neuroscience
Other Neuroscience
 $100.00M ▲$60.00M ▼$60.00M ▲$50.00M ▼
Other Products
Other Products
 $750.00M ▲$750.00M ▲$600.00M ▼$660.00M ▲
Ozurdex
Ozurdex
 $120.00M ▲$120.00M ▲$130.00M ▲$120.00M ▼
Qulipta
Qulipta
 $200.00M ▲$190.00M ▼$270.00M ▲$290.00M ▲
RINVOQ
RINVOQ
 $1.83Bn ▲$1.72Bn ▼$2.03Bn ▲$2.18Bn ▲
SKYRIZI
SKYRIZI
 $3.78Bn ▲$3.42Bn ▼$4.42Bn ▲$4.71Bn ▲
Ubrelvy
Ubrelvy
 $300.00M ▲$240.00M ▼$340.00M ▲$350.00M ▲
VENCLEXTA
VENCLEXTA
 $660.00M ▲$670.00M ▲$690.00M ▲$730.00M ▲
Vraylar
Vraylar
 $920.00M ▲$770.00M ▼$900.00M ▲$930.00M ▲
Restasis
Restasis
 $110.00M ▲$0 ▼$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement AbbVie’s revenue base is large and generally stable, but profits have come down from earlier peak years. The business still earns strong gross margins, showing its drugs command solid pricing power, yet operating and net income have been pressured as the company absorbs the loss of exclusivity on older blockbusters, invests in new products, and manages higher costs. Earnings per share today are much lower than a few years ago, which reflects this transition period. Overall, the income statement shows a mature, highly profitable pharma business in the middle of a shift from legacy products to newer growth drivers, with solid sales but more volatility in bottom‑line performance.

Balance Sheet

Balance Sheet The balance sheet is sizable and fairly stable in total assets, but it is also heavily leveraged. Debt remains high, even though it has been slowly worked down from prior years, while reported shareholder equity is quite small relative to the size of the company. That points to an aggressive use of debt and shareholder returns over time. The cash balance moves around year to year but is not especially large versus total obligations, so AbbVie relies more on its ongoing cash generation than on a big cash cushion. In short, the balance sheet is workable for a company with strong cash flows, but it leaves less room for major negative surprises.

Cash Flow

Cash Flow AbbVie’s cash flow profile is a major strength. The company consistently turns a large share of its revenue into cash from operations, and after only modest spending on capital investments, it retains a very high level of free cash flow. While cash generation has eased off from its best years, it remains robust enough to comfortably cover interest, research, acquisitions, and shareholder returns. This healthy cash engine helps offset concerns about leverage and provides financial flexibility to support the pipeline and strategic deals, even as earnings fluctuate.

Competitive Edge

Competitive Edge AbbVie holds a leading position in several important therapeutic areas and benefits from a wide, durable moat. The company successfully managed the decline of its former flagship drug by building up newer immunology medicines like Skyrizi and Rinvoq, which are becoming major franchises in their own right. The Allergan acquisition added powerful aesthetic and neuroscience brands such as Botox, giving AbbVie strong diversification beyond immunology. Its global sales infrastructure, deep relationships with physicians, and extensive patent portfolio make it hard for rivals to displace. The main competitive risk is the ongoing wave of biosimilar and branded competition against both older and newer drugs, but AbbVie’s breadth and brand strength provide meaningful defense.

Innovation and R&D

Innovation and R&D Innovation is central to AbbVie’s strategy. The company is using artificial intelligence, machine learning, advanced analytics, and automation across discovery, clinical trials, and manufacturing to speed development and improve success rates. Its pipeline is broad, with late‑stage programs in immunology, oncology, neuroscience, and other areas, plus targeted efforts in rare diseases and new mechanisms of action. Recent and ongoing acquisitions are being used to plug gaps, especially in oncology and neuroscience, and to bring in promising early‑stage assets. The opportunity is for these newer medicines to replace and surpass lost revenue from aging blockbusters; the risk is that clinical setbacks or slower‑than‑expected uptake could leave a gap in future growth.

Summary

AbbVie is a large, established biopharmaceutical company in the middle of a portfolio handoff from older, highly profitable drugs to a newer generation of treatments. Revenues remain strong and diversified, but profits have been compressed during this transition. The balance sheet carries significant debt, relying on the company’s very strong and steady free cash flow to remain comfortable. Competitively, AbbVie enjoys a wide moat supported by leading positions in immunology, aesthetics, and neuroscience, and it is leaning heavily on technology‑enabled R&D and strategic deals to sustain its pipeline. The key story going forward is execution: how effectively the company can grow its next wave of products and integrate acquisitions, while managing high leverage and the inevitable competitive and regulatory challenges in global pharma.

NEWS

November 28, 2025 · 7:01 AM UTC

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

Read more

November 25, 2025 · 9:30 AM UTC

AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec

Read more

November 24, 2025 · 8:00 AM UTC

AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference

Read more

November 18, 2025 · 12:47 PM UTC

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

Read more

November 13, 2025 · 8:30 AM UTC

AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™

Read more